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ABSTRACT Activation of the natriuretic peptide system
lowers blood pressure and causes the excretion of salt. Atrial
natriuretic peptide and B-type natriuretic peptide are the
humoral mediators of this effect; they act primarily by binding
to membrane-bound natriuretic peptide receptor A (NPRA)
and stimulating its intrinsic guanylate cyclase activity. To
study whether genetically determined differences in NPRA
expression affect blood pressure we have generated mice with
one, two, three, or four copies of the gene encoding NPRA
(Npr1 in the mouse). Atrial natriuretic peptide-dependent
guanylate cyclase activity ranged progressively from approx-
imately one-half normal in one-copy animals to twice normal
in four-copy animals (P < 0.001). On different diets (0.05%,
2%, and 8% NaCl), the blood pressures of F1 male mice having
only one copy of Npr1 averaged 9.1 mmHg (1 mmHg 5 133 Pa)
above those of wild-type two-copy males (P < 0.001), whereas
males with three copies of the gene had blood pressures
averaging 5.2 mmHg below normal (P < 0.01). The blood
pressures of the one-copy F1 animals were significantly higher
(by 6.2 mmHg; P < 0.01) on the high-salt than on the low-salt
diet. The blood pressures of four-copy F3 males were signifi-
cantly lower (by 7 mmHg; P < 0.05) on the high-salt than on
the low-salt diet. These results demonstrate that below normal
Npr1 expression leads to a salt-sensitive increase in blood
pressure, whereas above normal Npr1 expression lowers blood
pressures and protects against high dietary salt.
Essential hypertension is a complex disease in which blood
pressures are persistently high without identifiable cause. Both
genetic and environmental factors are influential (1). Al-
though a small number of individuals have been identified in
which hypertension is the consequence of single gene defects
that are inherited in a simple Mendelian fashion (2), the
pattern of inheritance in the majority of individuals is not clear,
suggesting that blood pressure, like many other quantitative
traits, is determined by the action of many genes.
The natriuretic peptide system affects blood pressure di-
rectly through its vasodilatory and natriuretic activities (3); it
also affects blood pressure indirectly, for example, by inhibiting
the reninyangiotensin system whose action raises blood pres-
sure (3). Genetic defects in the natriuretic peptide system are
consequently candidate contributors to essential hypertension.
Atrial natriuretic peptide (ANP), which induces a profound
natriuresis, diuresis, and hypotension upon infusion into rats,
was first discovered in 1981 by deBold et al. (4) in atrial
extracts. Two other related peptides, B-type (brain-type) na-
triuretic peptide (BNP) and C-type natriuretic peptide (CNP),
were subsequently isolated (5, 6). The major sites of synthesis
of ANP and BNP (as precursors) are in the heart, and after
release (as peptides) these hormones act primarily by binding
to natriuretic peptide receptor A (NPRA), a membrane-bound
form of guanylate cyclase (also known as guanylate cyclase-A
or GC-A) (7). The binding of ligand stimulates production of
cGMP, a second messenger, which relaxes smooth muscle,
induces natriuresis and diuresis in the kidney, and inhibits
aldosterone production in the adrenal glands. The third na-
triuretic peptide, CNP, mainly acts in the central nervous
system through binding to natriuretic peptide receptor B
(NPRB), also a guanylate cyclase type of receptor. All three
peptides bind to a third receptor, natriuretic peptide type C
receptor (NPRC), which lacks guanylate cyclase activity and is
thought to function as a clearance receptor.
The study of genetic traits in living animals has been
facilitated by gene targeting experiments in which desired
genetic changes are made in the mouse germ line. When the
trait of interest is quantitative, such as hypertension, rigorous
investigations into how changes in expression of a relevant
gene affect the phenotype of interest require great care in
maintaining an otherwise uniform genetic background (8).
The recently described method of gene titration (9, 10) pro-
vides a general strategy for implementing this type of inves-
tigation through analyses of mice that have an increased or
decreased number of copies of a chosen target gene at its
normal chromosomal location and controlled by its natural
regulatory elements. This strategy typically produces heterozy-
gous F1 offspring that are hybrids between the mouse strains
129 and C57BLy6 and have either one copy (1y0), two copies
(1y1, wild type), or three copies (2y1) of the target gene.
Because the resulting F1 animals are genetically identical
except at the target locus, any phenotypic differences can be
directly attributed to the changes in the target locus without
the complications of genes, linked or unlinked, that may differ
between the two strains of mice. By using this strategy, we have
previously demonstrated that genetically determined changes
in the level of expression of the angiotensinogen gene directly
cause changes in the blood pressures of mice, and that these
change are observable in animals that have all their normal
homeostatic mechanisms intact (10).
Accordingly, to investigate the effects of quantitative
changes in the natriuretic peptide system that are mediated by
NPRA, we have used gene targeting to disrupt and duplicate
the gene (Npr1) coding for NPRA in mice. The resulting F1
mice with one, two, or three copies of Npr1 and F3 mice with
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four copies establish a direct causative connection between
Npr1 expression, ANP-stimulated guanylate cyclase activity,
blood pressure, and its sensitivity to dietary salt.
MATERIALS AND METHODS
Gene Disruption and Gene Duplication by Homologous
Recombination. By using the published oligonucleotide se-
quence of the murine Npr1 cDNA (11) and the genomic
organization of the rat Npr1 gene (12) as guides, two probes
corresponding to exons 1 and 22 were generated by PCR with
mouse genomic DNA as a template. DNA fragments that
cover the entire Npr1 gene of a strain 129 mouse were isolated
as six overlapping l phage clones and mapped by restriction
enzyme digests.
The targeting construct and procedures for disrupting the
Npr1 gene have been described (13). The disruption replaced
exon 1, intron 1, and a portion of exon 2 with a copy of the
neomycin-resistance gene oriented oppositely from the Npr1
gene.
To duplicate the Npr1 gene, a targeting construct was made
(see Fig. 1 A) having a 6.5-kb fragment of strain 129 genomic
DNA from immediately upstream of the 59 coding region of
the gene as the 59 region of homology, with a 1.3-kb HindIII
fragment from 6 kb downstream of the coding region as the 39
region of homology. A neomycin-resistance cassette (NEO)
from pMC1neopolA was placed between the 59 and 39 regions
of homology, and the Herpes simplex thymidine kinase gene
from pMC1TK was inserted downstream of the 1.3-kb frag-
ment to allow for positive–negative selection (14). The em-
bryonic stem (ES) cell line BK4 was electroporated with the
linearized targeting construct, and the cells were cultured as
described (15). G418yganciclovir-resistant colonies were ex-
panded, and their DNA was analyzed by Southern blots after
digestion with XbaI and hybridization to a probe containing
exon 1 sequences. Cells having the duplicated Npr1 gene give
a 25-kb hybridizing fragment in addition to a 10.4-kb fragment
corresponding to the wild-type gene.
Generation of Mice with Various Copies of the Npr1 Gene.
Chimeras for the duplication experiment were made by inject-
ing targeted ES cells into blastocysts as described (16). Male
chimeras transmitting the duplicated Npr1 gene to their off-
spring were mated to strain B6 female mice. The resulting F1
129 3 B6 hybrid offspring, genotyped as described in the
following section, have either three copies (2y1) of the Npr1
gene or two copies (1y1, i.e., wild type). Chimeras generated
in the Npr1 disruption experiment (13) were mated to wild-
type B6 females to provide F1 129 3 B6 hybrid offspring with
one gene copy (1y0). Because the 129 and B6 parental mouse
strains are inbred, the F1 animals are genetically identical
except for the targeted gene. Intercrossing the 2y1 F1 het-
erozygotes produced F2 offspring with two, three, or four
copies (2y2) of the Npr1 gene. F3 animals having four copies
of the Npr1 gene were also generated as described in Results.
Mouse Genotype Analysis. Genotypes of the F1 animals
were determined by the same Southern blot analyses used to
identify targeted ES cells. Southern blot analysis cannot,
however, reliably distinguish F2 or F3 three-copy and four-copy
Npr1 offspring because both genotypes yield identical endog-
enous and targeted bands, which differ only in their relative
amounts—an unreliable estimate in many Southern blots.
Three- and four-copy offspring from matings between F1 or F2
animals were therefore distinguished by simple sequence
length polymorphism analysis by using the Massachusetts
Institute of Technology (MIT) markers D3MIT40 and
D3MIT101 (17). These markers are located on opposite sides
of the Npr1 gene at 2 and 3 centimorgans, respectively, and the
corresponding PCR fragments differ in length in strain 129 and
B6 animals. Typing for the markers allows determination of
whether a specific animal has a copy of the Npr1 locus derived
from strain 129 (and therefore has the genetically duplicated
locus) accompanied or unaccompanied by a copy of the locus
from strain B6 (the unaltered locus). PCR was performed on
purified-tail DNA by using the published D3MIT40 and
D3MIT101 primer sets and the PCR products were separated
by polyacrylamide gel electrophoresis to distinguish band sizes
characteristic of the two markers in strain 129 (110 bp and 124
bp) or in strain B6 (140 bp and 108 bp). For example, with
D3MIT40, a single band of 110 bp indicates a strain 129-
derived locus on both chromosomes, which in the F2 and F3
matings corresponds to a 2y2 (four-copy) genotype, whereas a
single band of 140 bp indicates a B6-derived locus on both
chromosomes, corresponding to a 1y1 (two-copy) mouse.
Bands of 110 bp and 140 bp indicate a heterozygous 2y1
(three-copy) genotype. With D3MIT101, a single band of 124
bp corresponds to a 2y2 genotype, a single band of 108 bp
corresponds to a 1y1 genotype, and bands of 108 bp and 124
bp indicate a 2y1 genotype. Animals having a discrepancy
between the two flanking markers, indicating a crossover
between them (about 5%), were not used for further analysis.
Guanylate Cyclase Assays. Plasma membrane preparations
were isolated as described (18) from tissues of 49–54-day-old
animals having one, two, three, or four copies of Npr1. Animals
were euthanized by anesthetic overdose. Dissected tissues were
homogenized in ice-cold buffer and centrifuged to remove
soluble cyclases. To determine cyclase activity, the membrane
pellets were incubated at 37°C in the presence of 1 mM
3-isobutyl-1-methyl-xanthine, 2 mM ATP, 2 mM GTP, 4 mM
MgCl2, 30 mM phosphocreatine, and 75 unitsyml creatine
kinase, with or without 1 mM ANP. At various times the
incubated samples were treated with 6% trichloracetic acid,
extracted with diethyl ether, and their cGMP content was
determined by radioimmunoassay (19). The results are ex-
pressed as picomoles of cGMP synthesized per milligram of
protein per minute, as determined by linear regression analysis
of 0-, 5-, and 10-min time points. The basal rate of cGMP
synthesis (with no ANP added before incubation) was sub-
tracted from the rate of total cGMP synthesis (with ANP
added immediately before incubation) to determine ANP-
stimulated cGMP synthesis.
Blood Pressure Measurements. All blood pressure measure-
ments were made on conscious young adult male mice (ranging
in age from 95–115 days) by a noninvasive computerized
tail-cuff method (20). Blood pressures were first measured in
animals that had been on low-salt chow (0.05% NaCl,
TD94025; Teklad, Madison, WI) for 2 weeks. After 7 days of
training, begun after approximately 1 week on the low-salt diet,
the blood pressures for each animal were taken by an individ-
ual who did not know the genotypes of the animals. Animals
were then placed on an intermediate-salt diet (2% NaCl,
TD96037; Teklad) for an additional 2 weeks, during which the
animals were retrained, and blood pressures were again mea-
sured. Finally, the animals were placed on a high-salt diet (8%
NaCl, TD96038; Teklad) for 2 weeks including a retraining
period and their blood pressures were measured. All blood
pressures were calculated as the average of 6–10 sessions per
day for 5 consecutive days. Statistical analyses were performed
by using ANOVA for repeated measures with salt and geno-
type as variables.
Organ Weights and Hematocrit Measurements. Tissues
were removed and weighed from animals euthanized by an-
esthetic overdose. Organ weights were recorded as the per-
centage of total body weight. Hematocrits were the mean of
the values obtained from each of three heparinized hematocrit
tubes of blood taken from animals anesthetized with avertin
(1.6 mg).
RESULTS
Gene Targeting. Disruption of the Npr1 gene was achieved
as described (13) by replacing exon 1, intron 1, and part of exon
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2 of the gene with a neomycin resistance gene (NEO). Ho-
mozygotes for this disruption synthesize no NPRA (13). The
principles of the method for duplicating genes by double-
strand gap repair have been described previously (9). Double-
strand gap repair uses the target gene as a template to fill in
a gap between two regions of homology that span the gene, and
a single crossover event completes the duplication event. The
result is two identical copies of the gene arranged in tandem
at the normal chromosomal locus. Fig. 1A illustrates the
specific targeting construct and homologous recombination
used with the Npr1 gene and the resultant duplicated locus.
The entire coding region of the gene, together with 6.5 kb of
sequence upstream of the Npr1 coding region and 7.3 kb of
sequence downstream of the last coding exon, are included in
the duplicated region, which totals 32 kb. This extensive
duplication was aimed at ensuring that all regulatory regions
are intact and duplicated. Correctly targeted ES cells, identi-
fied by Southern blot analysis of an XbaI digest of the cell DNA
(Fig. 1B) by using a probe containing exon 1 sequences,
occurred at a frequency of 1 in 9 doubly resistant colonies.
Three male chimeras mated to B6 females produced F1
offspring; approximately 50% of the pups carried the dupli-
cated locus as determined by Southern blot analysis of tail
DNA.
The relative survival of pups with different numbers of
functional copies of Npr1 was determined from 36 F1 3 F1
matings (1y0 3 1y0 and 2y1 3 2y1), which together produced
228 F2 progeny. The numbers of progeny at weaning having
zero, one, two, and three copies of the Npr1 gene conformed
to normal Mendelian expectations, as did the numbers of
four-copy females. However, there was a deficiency of male
four-copy pups (12 expected, 2 observed; P , 0.05 by x2). F2
males having three or four copies of Npr1 were therefore
crossed with the four-copy F2 females to produce F3 offspring
having three or four copies of the gene. These matings
produced three-copy and four-copy progeny in essentially
equal numbers (as expected) regardless of gender. Because of
the difficulty of producing F2 male mice, F3 animals were used
for studies of four-copy mice.
Copy Number-Dependent ANP-Stimulated cGMP Produc-
tion in Mutant Mice. NPRA is a member of the guanylate
cyclase family of receptors, which produce cGMP in response
to ligand binding. NPRA elevates intracellular levels of cGMP
when ANP binds to the extracellular domain of the receptor
and allosterically activates its guanylate cyclase catalytic do-
main (21). To quantitate the biochemical consequences of
altering the number of copies of the Npr1 gene, we measured
ANP-dependent cGMP synthesis in membrane preparations
from the various mutant animals and from controls. Fig. 2
shows the rates of ANP-dependent cGMP synthesis in lung and
kidney membrane preparations from F1 animals with one, two,
and three copies of the Npr1 gene and from F3 animals with
four copies. The relative activities of one-, two-, three-, and
four-copy animals, respectively 42%, 100% (by definition),
146%, and 199% in the lungs, and 46%, 100% (by definition),
186%, and 204% in the kidneys, demonstrate a linear and
essentially direct proportionality between Npr1 gene copy
number and ANP-dependent guanylate cyclase activity (P ,
0.001 by ANOVA, r2 5 0.96 by linear regression analysis).
Thus, the expression of NPRA protein as measured by the rate
of ANP-stimulated cyclase activity is directly proportional to
the Npr1 gene copy number. We infer that Npr1 gene expres-
sion at the mRNA level follows the same direct proportion-
ality.
Blood Pressures in Npr1 Mutant Animals. The natriuretic
peptideyguanylate cyclase signaling system is generally
thought to oppose the reninyangiotensinyaldosterone system
by serving as a vasodilating system and as a regulator of blood
volume and thence of blood pressure (22). To ascertain the
effect of changes in expression of the Npr1 gene on blood
pressures, and to determine whether animals with different
steady-state levels of NPRA are able to maintain a stable blood
pressure across a wide range of dietary sodium concentrations,
animals were placed on low-(0.05% NaCl), intermediate-
(2.0% NaCl), and high-(8% NaCl) salt diets, and their blood
pressures were measured by a noninvasive computerized tail-
cuff method (20). The tail-cuff system allows a longitudinal
study of pressures to be made in the same animals while their
dietary sodium intakes are changed. Fig. 3 presents tail-cuff
blood pressure measurements on F1 and F3 males (12 per
genotype) on each of the three diets. The data clearly establish
that changes in the Npr1 gene copy number, and hence of
NPRA expression, cause progressive changes in blood pres-
sures at any of the three dietary salt concentrations (P , 0.0001
for effect of genotype by ANOVA for repeated measures).
Blood pressures of the F1 generation mice having only one
copy of Npr1 averaged 9.1 mmHg (1 mmHg 5 133 Pa) above
normal (P , 0.001); F1 mice with three functional copies of the
gene had blood pressures that average 5.2 mmHg below
normal (P , 0.01). There was a significant effect of salt on
blood pressure in one-copy animals (P , 0.01, contrast of
means, low salt versus high salt, by ANOVA for repeated
measures), but not in animals having two or three copies of
Npr1. Blood pressures in the F3 generation animals having four
copies of Npr1 were negatively affected by increasing dietary
salt (P , 0.05 for salt effect by ANOVA for repeated mea-
sures).
FIG. 1. Targeted duplication of the murine Npr1 gene. (A) Ho-
mologous recombination and targeting construct. The endogenous
Npr1 locus is shown schematically in the top line. The duplication
targeting construct (middle line) uses a 6.5-kb 59 region of homology
from immediately upstream of the Npr1 coding region. The 39 region
of homology is a 1.3-kb fragment located approximately 6 kb down-
stream of exon 22. A 24-kb gap (indicated) is repaired during the
recombination and a single crossover event leads to a 32-kb duplica-
tion, which includes the complete Npr1 gene and upstream and
downstream flanking sequences. The bottom line shows the resultant
locus with the two copies of Npr1 in tandem arrangement separated by
the neomycin-resistant gene (NEO) (not drawn to scale). 3, XbaI sites;
p, position of the probe. (B) Southern blots. Correctly targeted clones
are identified after digesting ES cell DNA with XbaI and hybridizing
with a probe corresponding to exon 1 of Npr1. The probe hybridizes
to both 10.4- and 25-kb bands in the duplicated chromosome, but only
to a 10.4-kb band in the unmodified chromosome.
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General Features of the One- Through Four-Copy Mutant
Animals. Several general measurements were carried out with
the one- through four-copy animals, including hematocrit,
body weight, and weights of the kidney, lung, and heart. The
resulting data (not shown) revealed no significant effects of
this spectrum of Npr1 genotypes on any of the parameters.
Histological evaluation of the hearts, lungs, and kidneys were
also unremarkable (data not shown).
DISCUSSION
The chief observations made on the animals with one, two,
three, and four copies of the Npr1 gene are: (i) ANP-stimulated
cGMP synthesis increases essentially in direct proportion to
the number of Npr1 genes, ranging from 42% and 46% normal
in lungs and kidneys in animals with one copy of Npr1 to 199%
and 204% normal in four-copy animals. (ii) Tail-cuff blood
pressures decrease as Npr1 copy number and NPRA expres-
sion increases, with one-copy F1 males exhibiting blood pres-
sures an average of 9.1 mmHg above wild-type controls, and
three-copy F1 animals averaging 5.2 mmHg below controls; the
average effect of Npr1 copy number is 7.2 6 2.1 mmHg per
copy (correlation coefficient 0.60; P , 0.01). (iii) No differ-
ences among the one-copy through four-copy genotypes were
observed in hematocrits, organ weights, or histology of hearts,
lungs, and kidneys. (iv) The blood pressures of the two- and
three-copy F1 animals are not affected by changes in dietary
salt over the range 0.05%, 2%, and 8%, but the one-copy F1
animals have blood pressures significantly higher when main-
tained on high-salt diet than on low-salt diet (by 6.2 mmHg),
and the four-copy F3 animals show a significant decrease in
blood pressure (6.9 mmHg) as dietary salt is increased from
0.05% to 8%.
Several conclusions follow from these observations. First,
genetically determined quantitative changes in the expression
of the Npr1 gene cause inverse changes in the blood pressures
of mice that are otherwise genetically wild type and have all
their normal homeostatic mechanisms intact. Thus, quantita-
tive changes in the gene coding for NPRA, like that coding for
angiotensinogen (10), directly affect blood pressures in other-
wise normal mice. This is consistent with the previously
published observation that mice completely lacking NPRA
have elevated blood pressures (13, 23). The second conclusion
is that NPRA expression affects the sensitivity of blood
pressure to dietary salt: the one-copy F1 animals show small
but statistically significant increases in pressure with increases
in salt, whereas the four-copy F3 animals show small but also
statistically significant decreases in pressure with increases in
salt. Thus the Npr1 gene, like the gene coding for ANP, is a
candidate for directly affecting the sensitivity of blood pressure
to salt. The effects of decreased expression of Npr1 on the
sensitivity of blood pressure to dietary salt in this study of
heterozygous one-copy F1 mice differ from the absence of an
effect reported by Lopez et al. (23) and by us (13) in F2 animals
heterozygous (one-copy) for an Npr1 disruption. This differ-
ence is likely related to the greater difficulty of observing small
genetic effects in F2 animals versus F1 animals (see ref. 8 for
a discussion of this difficulty). Our conclusion that the ANP–
NPRA system is a determinant of basal levels of blood pressure
is in agreement with the findings from previous experiments by
using genetically altered animals. Thus, transgenic mice with
constitutive expression of the murine ANP gene in hepatocytes
and a 5-fold normal plasma ANP level have blood pressures 25
mmHg lower than normal (24). A reduction of blood pressure
in transgenic mice with 10- to 100-fold normal plasma levels of
BNP has also been reported (25). Conversely, a genetic
FIG. 2. Guanylate cyclase activity as a function of Npr1 gene copy number. Ordinate gives the rate of ANP-stimulated cGMP synthesis in lung
(A) and kidney (B) membrane preparations from both male and female animals with one, two, three, and four copies of the Npr1 gene as a percent
of the rate of normal two-copy animals. Solid squares represent the means of five animals for each genotype. Error bars represent the SEMs.
FIG. 3. (A) Tail-cuff blood pressures of male F1 animals having one, two, or three copies of the Npr1 gene. Twelve animals for each genotype
were successively fed diets containing the indicated content of NaCl. (B) Tail-cuff blood pressures of male F3 mice having four copies of Npr1 (n 5
12) and fed the same diets. (Results of the four-copy mice are graphed separately because the F3 mice are genetically distinct from the F1 animals.)
Vertical bars represent mean values of each group of animals. Error bars represent SEMs. p, P , 0.001 compared with two-copy controls; †, P ,
0.01 compared with two-copy controls; ‡, P , 0.05 compared with 0.05% salt.
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decrease in ANP production causes a salt-sensitive increase in
the blood pressure of mice (26). In addition, Weidman et al.
(27) have reported that the plasma ANP concentrations in
children of two normotensive parents are higher than in
children with a hypertensive parent, especially when the chil-
dren ingest a high amount of salt, and Deng and Rapp (28)
have demonstrated that specific alleles of the gene encoding
NPRA in rats segregate with the blood pressure response to
high salt intake in F2 hybrids between Milan salt-insensitive
normotensive and Dahl salt-sensitive hypertensive rats.
Most importantly, the present ‘‘gene titration’’ experiments
with the Npr1 gene in mice support two concepts. First, genetic
alterations in the expression at the mRNA andyor protein level
of the several protein-encoding genes that we have studied by
gene titration [Agt (9), Ace (29), and Npr1], even in complex
highly regulated biological systems like those controlling blood
pressure, are not subject to direct feedback regulation by their
products because the protein concentrations are essentially
proportional to gene copy number. Second, genetically deter-
mined changes in the level of expression of an increasing
variety of genes directly cause changes in blood pressure
despite the existence of homeostatic systems. The degree to
which these concepts are relevant to the genetic control of
essential hypertension in humans depends on the existence and
frequency in human populations of naturally occurring vari-
ants of the corresponding genes and on the degree to which the
variants change expression. One such variant has been de-
scribed for the human AGT gene (30, 31). Our present work
strongly suggests that genetic polymorphisms affecting the
level of expression of the human gene coding for NPRA, if they
exist, would also be of importance in determining the inher-
itance of higher or lower than normal blood pressures, and
perhaps of their sensitivity to dietary salt.
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